Indian pharma sees little immediate threat in Trump’s 200% tariff plan
Indian pharmaceutical leaders expressed minimal concern over US President Donald Trump's proposed 200% tariff on generic drugs, as the current zero tariff will remain for two more years. The industry views the extended zero tariff period as a relief, especially since the US is its largest foreign market. However, experts noted that ongoing tariff instability has already prompted a shift away from the US market in the past year.